Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. The company engages in the aerosol delivery of non-psychoactive cannabinoids to the blood stream for treatment of chronic pain, post-traumatic stress disorder, insomnia, surgery recovery, and other ailments. It offers pressurized meter dose inhaler, a device that delivers a measured amount of aerosolized inhalant in a mist to the lungs; sublingual oral spray devices; and water-soluble cannabidiol and cannabigerol isolates under the nhaler brand. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Dallas, Texas. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc.

Rapid Therapeutic Science Laboratories, Inc. trades as RTSL on OTC. The company is classified in Healthcare / Medical - Devices and reports in USD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$183,296 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Rapid Therapeutic Science Laboratories, Inc. can be compared against peers such as Hempfusion Wellness Inc., Cantabio Pharmaceuticals, Inc., Diagnocure, Inc., Humanigen, Inc., MagForce AG, NutraLife BioSciences, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $52,994, beta of -1.86, and return on equity of +5.9%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

RTSL currently shows total debt of $3.45M and beta of -1.86. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.rtslco.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.